Study of ER (Estrogen Receptor), PR (Progesterone Receptor) & HER-2/NEU(Human Epidermal Growth Factor Receptor) expression by immunohistochemistry in breast carcinoma
DOI:
https://doi.org/10.7439/ijbar.v5i6.787Abstract
Introduction: Over the last few decades there have been outstanding advances in breast cancer management leading to early detection and treatment of disease. Recent attention has been directed to Immunohistochemistry-based classification of both Estrogen Receptor/Progesterone Receptor and Human epidermal growth factor receptor/neu status which provides prognostic and therapeutic information and is inexpensive and readily available. Aim: The present study was undertaken with the view of correlating the histopathology of the tumor by way of tumor grade, various traditional prognostic markers and its Immunohistochemistry profile with respect to Estrogen/Progesterone hormone receptors and Human epidermal growth factor receptor/neu status. Material and Methods : 43 patients with breast neoplasm who were diagnosed to have carcinoma breast, after undergoing preliminary FNAC/Trucut biopsy/open biopsies and subsequently underwent Modified radical mastectomy were included in the study. The surgical specimen were then evaluated histopathologically and immunohistochemically for ER, PR, HER-2/neu markers. Results: Out of 43 cases studied, Majority of the cases {41cases (95.34%)} were of Invasive ductal carcinoma. Grade I tumors were seen in patients more than 60 years of age implying a better prognosis.Percentage of ER positivity was 39.5%, PR positivity was 41.8%, Her2/Neu positivity was 32.5%. Only case was triple positive for all the three markers (ER/PR+ Her2+) which was in the 71-80 yrs age group implying a better predictive response to hormonal therapy. Conclusion : From the present study it was concluded that with incorporation of Immunohistochemistry-based classification of both ER/PR and HER-2/neu status into the histopathology report using the traditional TNM staging and histological grading of breast carcinoma help in better therapeutic management and increases prognostic accuracy and is inexpensive and readily available.Downloads
Download data is not yet available.
Downloads
Published
2014-06-30
Issue
Section
Original Research Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
How to Cite
Study of ER (Estrogen Receptor), PR (Progesterone Receptor) & HER-2/NEU(Human Epidermal Growth Factor Receptor) expression by immunohistochemistry in breast carcinoma. (2014). International Journal of Biomedical and Advance Research, 5(6), 275-278. https://doi.org/10.7439/ijbar.v5i6.787